Lilly offers every Zepbound dose as a single-dose vial through LillyDirect

Eli Lilly announced on June 16, 2025 that the two highest approved doses of Zepbound (tirzepatide) — 12.5 mg and 15 mg — would be sold as single-dose vials for $499 per month through LillyDirect's Self Pay Pharmacy Solutions and the Zepbound Self Pay Journey Program ^[3]. Health care providers could begin prescribing the two vial strengths on July 7, 2025, with shipments to patients beginning in early August ^[3].

The move completed the vial lineup. With the 12.5 mg and 15 mg added, all six approved strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — became available in single-dose vials for $499 a month or less to any eligible adult with obesity and a valid prescription, regardless of insurance status ^[3]. The 2.5 mg starter dose was priced at $349 for the first month, followed by $499 for the 5 mg dose ^[3].

The pricing fine print

The $499 figure was a discount off the regular self-pay prices, which Lilly listed as $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg and $1,049 for 15 mg ^[3]. The reduced price applied to the first fill and to refills placed within 45 days of the previous delivery ^[3]. In other words, patients who let a refill lapse beyond that window could pay the higher list amount — Lilly later spelled this out explicitly, noting the 12.5 mg and 15 mg vials are priced at $849 and $1,049 if refilled outside the 45-day window ^[2].

"Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions," said Rhonda Pacheco, group vice president of U.S. Cardiometabolic Health at Lilly, in the announcement ^[3]. Lilly also pointed to resources on its Zepbound website offering step-by-step guidance for appealing insurance coverage denials and submitting letters of medical necessity ^[3].

Zepbound is approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity ^[1]. In a 72-week study of adults without diabetes, average weight loss was 15.0% (34 lbs) at 5 mg, 19.5% (44 lbs) at 10 mg, 20.9% (48 lbs) at 15 mg, and 3.1% (7 lbs) on placebo ^[3]. About 36.2% of people on 15 mg lost at least 25% of body weight, though Lilly noted that analysis was less rigorous and may be due to chance ^[3].

Why it matters for patients

Before this change, people who titrated up to the highest maintenance doses had fewer low-cost self-pay options; the vial program covered only lower strengths. After early August 2025, someone paying cash at 15 mg could get the vial at $499 rather than the $1,049 regular price, as long as they stayed inside the 45-day refill window ^[3].

That window is the practical catch. The discount is tied to refilling on schedule, so gaps caused by travel, side effects, supply issues or a pause in treatment could mean a much higher bill on the next fill ^[2][3]. The program is a self-pay route, separate from insurance coverage, and Lilly framed it as an option while it continues pushing for broader coverage ^[3].

Zepbound also comes as single-dose pens in the same six strengths ^[1][3], so the vial price does not necessarily reflect what a patient using pens would pay. The sources do not break out how many people used the self-pay vial route.

What happens next

Prices have since moved. On Nov. 6, 2025, Lilly announced lower prices for Zepbound multi-dose pens, subject to FDA approval ^[2]. On Dec. 1, 2025, the company cut single-dose vial prices again under the Self Pay Journey Program: $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg, 10 mg, 12.5 mg and 15 mg ^[2]. A multi-dose KwikPen became available Feb. 23, 2026 ^[1].